• Find people
• Intranet

Urological Cancer Joaquim Bellmunt

Publications 2025 (13)

• Lloreta J^*, Marin J, Juanpere N, Pascual S, Gimeno J, Naranjo-Hans D, Segalés L, Hernández-Llodrà S, Simón M, Serrano L, Casado B, Lloveras B, Gea J. Muscle disease in severe COVID-19 patients: a microangiopathic myopathy. Ultrastruct Pathol 2025; 49(3): 296-305.
  Cites:0
  Cites:0
• Mato X, Kim SK, Jourdon A, Ma S, Choi SH, Giani AM, Paredes MI, Tebbenkamp ATN, Liu F, Duque A, Vaccarino FM, Sestan N, Colantuoni C, Rakic P, Santpere G^*, Micali N^*. Early developmental origins of cortical disorders modeled in human neural stem cells. Nat Commun 2025; 16(1): 6347.
• Pinto Á^*, Rocriguez M, Gómez-Iturriaga A, Rodríguez-Vida A, Vallejo-Casas JA, Castro E. The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review. Crc Cr Rev Oncol-Hem 2025; 210: 104678.
  Cites:0
  Cites:0
• Segalés L, Bellmunt J, Perera J, Vargas-Parra G, Juanpere N, López D, Rodríguez-Vida A, Colomo L, Cecchini L, Lloreta J, Yelamos J, Fumadó L, Hernández-Llodrà S^*. Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer. Lab Invest 2025; 105(6): 104171.
  Cites:0
  Cites:0
• Vidal N, Climent MA, Pérez S, Mendez-Vidal MJ, Anguera G, Martínez-Salas I, Gallardo E, Cuéllar-Rivas MA, Molina-Cerrillo J, Martín A, Rodríguez-Vida A, Almagro-Casado E, Gonzalez M, Domenech M, Martínez-Kareaga M, Fernández-Calvo O, Villa-Guzmán JC, Vázquez-Estevez S, González del Alba A^*, Puente J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clin Transl Oncol . 2025; 27(5): 2220-2231.
  Cites:0
  Cites:0
• Ajami T^*, Villalba-Lázaro E, Trilla-Herrera E, Ferreiro-Pareja C, Abella-Serra A, Francés A, Valdes-Figueroa N, Aguayo-Eldredge CA, López-Costea MA, Pérez-Reggeti JI, González-Satué C, Bernal-Salguero S, Delgado-Ortega G, Cecchini L, Ribal MJ, Musquera M, Lorente-García D, Section Of Uro-Oncology Of Catalan Urologic Society. Multicenter study of active surveillance for small renal masses: Real world practice pattern. Urol Oncol 2025; 43(5): 334.e1-334.e6.
  Cites:0
  Cites:0
• Afferi L^*, Jahn B, Kelkar AH, Dijk SW, Feldman ZM, Ward ZJ, Moschini M, Cathomas R, Bellmunt J, Gallioli A, Breda A, Fankhauser CD, Mattei A, Chang SL, Siebert U. Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis. World J Urol 2025; 43(1): 197.
  Cites:1
  Cites:1
• Gillessen S^*, Tombal B, Turco F, Choudhury A, Rodríguez-Vida A, Gallardo E, Velho PI, Nolè F, Cruz F, Loriot Y, McDermott R, Roumeguere T, Daugaard G, Yamamura R, Bompas E, Maroto P, Polo MH, da Trindade KM, Preto DD, Skoneczna I, Lecouvet F, Coens C, Fournier B, Saad F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. Eur Urol 2025; 87(3): 285-288.
  Cites:6
  Cites:6
• Boll LM, Vázquez-Montes de Oca S, Espinosa M, Castelo R, Bellmunt J^*, Perera J^*, Albà MM^*. Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. Nat Commun 2025; 16(1): 1213.
  Cites:1
  Cites:1
• Amat-Fernandez C, Pardo Y^*, Ferrer M, Bosch-Duran G, Lizano C, Briseño-Renata R, Vernet-Tomas M, Fumadó L, Beisani M, Redondo D, Bach-Pascual A, Garin O^*, Hospital de Mar Patient-Reported Measures Group (...,Pont A, Zamora V, Argudo N, Bach-Pascual A, Benaiges D, Castells X, Cecchini L, Chamoun B, Hurtado-Ortuño M, Noguera A, Perez-Piñero M, Pérez Sáez MJ, Servitja S, Villatoro M, Valderas JM,...). Evaluating the implementation of PROMs and PREMs in routine clinical care: co-design of tools from the perspective of patients and healthcare professionals. Health Qual Life Outcomes 2025; 23(1): 15.
• Monteiro FSM^*, Alencar-Junior AM, Da Trindade KM, Rebelatto TF, Maluf FC, Gazzola AA, Barrios PM, Bellmunt J, De Jesus RG, Silva GEB, Teixeira-Junior AAL, Spiess PE, Fay AP. Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study. Oncologist. 2025; 30(2): oyae220.
  Cites:0
  Cites:0
• Pal SK^*, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama BP, Rodríguez-Vida A, Roghmann F, Sevillano-Fernandez E, Matin SF, Loriot Y, Sridhar SS, Sonpavde G, Fleming MT, Lerner SP, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. Eur Urol 2025; 87(2): 271-274.
  Cites:0
  Cites:0
• Hernández A, Rodríguez-Vida A, Cardona L, Qin M, Arpí O, Soria-Jiménez L, Menéndez S, Quimis F, Galindo M, Arriola E, Salido M, Juanpere N, Rojo F, Muntasell A, Albanell J, Rovira A, Bellmunt J^*. Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. Mol Oncol 2025; 19(1): 151-172.
  Cites:4
  Cites:4